Latest From Biotech Now

Tony Coelho: A Patient Advocate’s Perspective on Paying for Value


Yesterday, Health Affairs published an op-ed by Tony Coelho, Former Member of the U.S. House of Representatives and Chairman of the Partnership to improve patient care, on the benefit of patient-centered outcomes research to better inform medical care, without limiting patients’ and providers’ choices. As Coelho writes, ‘The movement to place greater financial risk on providers in an effort to pay for value rather than volume will have the effect of fundamentally changing the way Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Answering the Call for Cures in Michigan

21st Century Cures Act

This week, the Kalamazoo Gazette published an op-ed on how we can accelerate the discovery, development and delivery of treatments and cures for patients written by Stephen Rapundalo, President and CEO of MichBio, and BIO’s Jim Greenwood. The op-ed highlights the focus of roundtable discussions being held across the country as part of the 21st Century Cures Initiative. The U.S. House of Representatives’ Energy and Commerce Committee launched the initiative – led by Chairman Fred Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

USDA Illuminates the Economic Benefits of Moving Toward a Biobased Economy

USDA biopreferred

“A bioeconomy is one based on the use of research and innovation in the biological sciences to create economic activity and public benefit.” - White House (2012) The U.S. Department of Agriculture (USDA)  Secretary Tom Vilsack has recently announced the release of a comprehensive report synthesizing current literature that explores opportunities in the emerging bioeconomy.  The report, entitled Why Biobased?, was created by the USDA as a precursor for a more comprehensive economic study to be released in the coming months by the USDA BioPreferred Read More >

Environmental & Industrial  |  Leave a comment  |  Email This Post
Tags: , , , , ,

2014 BIO Investor Forum Fireside Chat with Nick Leschly and Chris Collins

bluebird bio

Nick Leschly has served as bluebird bio’s president and chief executive officer since September 2010. Previously, he served as interim chief executive officer from March 2010 to September 2010. Formerly a partner of Third Rock Ventures, L.P. since its founding in 2007, Mr. Leschly played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Blurred Lines: Investors Explain Their Re-Thinking of Traditional Private-Only or Public-Only Investment Strategies


The recent expansion and acceleration of the biotech stock market has seen a new willingness and in some cases eagerness to pursue crossover investing in firms pre- and post-IPO. Venture capitalists have become less dogmatic about funding stage and equity share when positive returns seem nearly guaranteed and investment banks are engaging in discussions with entrepreneurs earlier than ever. Relatedly, corporate venture capital executives’ missions have broadened to consider more diverse forms of collaboration than Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,